MA28774B1 - SOLID DOSING FORM OF WET HEPARIN - Google Patents
SOLID DOSING FORM OF WET HEPARINInfo
- Publication number
- MA28774B1 MA28774B1 MA29506A MA29506A MA28774B1 MA 28774 B1 MA28774 B1 MA 28774B1 MA 29506 A MA29506 A MA 29506A MA 29506 A MA29506 A MA 29506A MA 28774 B1 MA28774 B1 MA 28774B1
- Authority
- MA
- Morocco
- Prior art keywords
- heparin
- wet
- dosing form
- pharmaceutical composition
- solid dosing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/609—Amides, e.g. salicylamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
L'invention concerne une composition pharmaceutique solide (telle qu'une forme de dosage solide) comprenant un agent d'administration et de l'héparine mouillée. L'inclusion d'héparine mouillée provoque, dans la composition pharmaceutique solide, beaucoup plus qu'une héparine non mouillée, une administration accrue de l'héparine. Sans aucun lien avec une théorie particulaire, les inventeurs estiment que du fait que la chaîne polymère d'héparine mouillée est déjà une forme « ouverte », alors que l'héparine non mouillée ne l'est pas, moins d'héparine mouillée est décomposée dans le tractus gastro-intestinal et est plus facilement absorbée dans l'estomac.The invention relates to a solid pharmaceutical composition (such as a solid dosage form) comprising a delivery agent and wet heparin. The inclusion of wet heparin causes, in the solid pharmaceutical composition, much more than a non-wetted heparin, increased administration of heparin. Without any connection with a particular theory, the inventors believe that because the wet heparin polymer chain is already an "open" form, while the non-wetted heparin is not, less wet heparin is decomposed in the gastrointestinal tract and is more easily absorbed into the stomach.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US56947504P | 2004-05-06 | 2004-05-06 | |
US57267904P | 2004-05-19 | 2004-05-19 | |
US59897804P | 2004-08-04 | 2004-08-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA28774B1 true MA28774B1 (en) | 2007-08-01 |
Family
ID=35320730
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA29506A MA28774B1 (en) | 2004-05-06 | 2006-12-04 | SOLID DOSING FORM OF WET HEPARIN |
Country Status (14)
Country | Link |
---|---|
US (1) | US8039018B2 (en) |
EP (1) | EP1750729A2 (en) |
JP (1) | JP2007536268A (en) |
KR (1) | KR20070008720A (en) |
AU (1) | AU2005240206B2 (en) |
BR (1) | BRPI0510226A (en) |
CA (1) | CA2564866A1 (en) |
EC (1) | ECSP067050A (en) |
IL (1) | IL178846A0 (en) |
MA (1) | MA28774B1 (en) |
MX (1) | MXPA06012841A (en) |
NZ (1) | NZ550894A (en) |
RU (1) | RU2006138703A (en) |
WO (1) | WO2005107773A2 (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8273794B2 (en) * | 2004-05-14 | 2012-09-25 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
AU2008316634B2 (en) * | 2007-10-24 | 2014-02-27 | Mannkind Corporation | Method of preventing adverse effects by GLP-1 |
WO2011097148A2 (en) * | 2010-02-04 | 2011-08-11 | Parsons Lowell C | Use of oral heparin preparations to treat urinary tract diseases and conditions |
DK3326620T3 (en) | 2010-12-16 | 2020-05-25 | Novo Nordisk As | SOLID COMPOSITIONS CONTAINING A GLP-1 AGONIST AND SALT OF N- (8- (2- HYDROXYBENZOYL) AMINO) CAPRYLIC ACID |
RU2602601C2 (en) | 2011-04-12 | 2016-11-20 | Ново Нордиск А/С | Double acylated glp-1 derivatives |
AU2013234496B2 (en) | 2012-03-22 | 2017-07-27 | Novo Nordisk A/S | Compositions of GLP-1 peptides and preparation thereof |
HUE042757T2 (en) | 2012-03-22 | 2019-07-29 | Novo Nordisk As | Compositions comprising a delivery agent and preparation thereof |
EP2827845B1 (en) | 2012-03-22 | 2018-12-26 | Novo Nordisk A/S | Compositions comprising a delivery agent and preparation thereof |
US9993430B2 (en) | 2012-06-20 | 2018-06-12 | Novo Nordisk A/S | Tablet formulation comprising semaglutide and a delivery agent |
ES2960687T3 (en) | 2018-02-02 | 2024-03-06 | Novo Nordisk As | Solid compositions comprising a GLP-1 agonist and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant |
TWI829687B (en) * | 2018-05-07 | 2024-01-21 | 丹麥商諾佛 儂迪克股份有限公司 | Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid |
Family Cites Families (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3510561A (en) | 1965-05-20 | 1970-05-05 | Canada Packers Ltd | Sulfone-enhanced heparin absorption through mucous membranes |
US5578323A (en) | 1992-06-15 | 1996-11-26 | Emisphere Technologies, Inc. | Proteinoid carriers and methods for preparation and use thereof |
US5541155A (en) | 1994-04-22 | 1996-07-30 | Emisphere Technologies, Inc. | Acids and acid salts and their use in delivery systems |
US5714167A (en) | 1992-06-15 | 1998-02-03 | Emisphere Technologies, Inc. | Active agent transport systems |
US6221367B1 (en) | 1992-06-15 | 2001-04-24 | Emisphere Technologies, Inc. | Active agent transport systems |
US5629020A (en) | 1994-04-22 | 1997-05-13 | Emisphere Technologies, Inc. | Modified amino acids for drug delivery |
US6331318B1 (en) | 1994-09-30 | 2001-12-18 | Emisphere Technologies Inc. | Carbon-substituted diketopiperazine delivery systems |
US5693338A (en) | 1994-09-29 | 1997-12-02 | Emisphere Technologies, Inc. | Diketopiperazine-based delivery systems |
US6916489B2 (en) | 1992-06-15 | 2005-07-12 | Emisphere Technologies, Inc. | Active agent transport systems |
US6610329B2 (en) | 1993-04-22 | 2003-08-26 | Emisphere Technologies Inc. | Compositions for the delivery of antigens |
US20040062773A1 (en) | 1993-04-22 | 2004-04-01 | Emisphere Technologies Inc. | Compositions for the delivery of antigens |
US5643957A (en) | 1993-04-22 | 1997-07-01 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
US20010003001A1 (en) | 1993-04-22 | 2001-06-07 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
SE9302135D0 (en) | 1993-06-18 | 1993-06-18 | Kabi Pharmacia Ab | NEW PHARMACEUTICAL COMPOSITION |
US5650386A (en) | 1995-03-31 | 1997-07-22 | Emisphere Technologies, Inc. | Compositions for oral delivery of active agents |
US5965121A (en) | 1995-03-31 | 1999-10-12 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
US6001347A (en) | 1995-03-31 | 1999-12-14 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
US5866536A (en) | 1995-03-31 | 1999-02-02 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
BR9604880A (en) | 1995-03-31 | 1998-05-19 | Emisphere Tech Inc | Compound composition dosage unit form methods for administering a biologically active agent for preparing a composition for administering an active agent and for preparing a compound and pharmacological composition |
US5989539A (en) | 1995-03-31 | 1999-11-23 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
US5820881A (en) | 1995-04-28 | 1998-10-13 | Emisphere Technologies, Inc. | Microspheres of diamide-dicarboxylic acids |
US5750147A (en) | 1995-06-07 | 1998-05-12 | Emisphere Technologies, Inc. | Method of solubilizing and encapsulating itraconazole |
AU2595697A (en) | 1996-03-29 | 1997-10-22 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
JP2000512671A (en) | 1996-06-14 | 2000-09-26 | エミスフェアー テクノロジーズ インク | Microencapsulated fragrance and preparation method |
US6391303B1 (en) | 1996-11-18 | 2002-05-21 | Emisphere Technologies, Inc. | Methods and compositions for inducing oral tolerance in mammals |
US6358504B1 (en) | 1997-02-07 | 2002-03-19 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
US6313088B1 (en) | 1997-02-07 | 2001-11-06 | Emisphere Technologies, Inc. | 8-[(2-hydroxy-4-methoxy benzoyl) amino]-octanoic acid compositions for delivering active agents |
IN186245B (en) | 1997-09-19 | 2001-07-14 | Ranbaxy Lab Ltd | |
WO1999044642A1 (en) | 1998-03-05 | 1999-09-10 | Phares Pharmaceutical Research Nv | Pharmaceutical compositions and their use |
US6949816B2 (en) * | 2003-04-21 | 2005-09-27 | Motorola, Inc. | Semiconductor component having first surface area for electrically coupling to a semiconductor chip and second surface area for electrically coupling to a substrate, and method of manufacturing same |
IL140710A0 (en) | 1998-07-27 | 2002-02-10 | Emisphere Tech Inc | Pulmonary delivery of active agents |
US6440929B1 (en) | 1998-07-27 | 2002-08-27 | Emisphere Technologies, Inc. | Pulmonary delivery of active agents |
CN1313439C (en) | 1998-08-07 | 2007-05-02 | 艾米斯菲尔技术有限公司 | Compounds and compositions for delivering active agents |
US6627228B1 (en) | 1999-01-08 | 2003-09-30 | Emisphere Technologies, Inc. | Polymeric delivery agents and delivery agents compounds |
AU3357800A (en) | 1999-02-05 | 2000-08-25 | Emisphere Technologies, Inc. | Method of preparing alkylated salicylamides |
AU3492100A (en) | 1999-02-11 | 2000-08-29 | Emisphere Technologies, Inc. | Oxadiazole compounds and compositions for delivering active agents |
AU3378100A (en) | 1999-02-26 | 2000-09-14 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
IL145546A0 (en) | 1999-04-05 | 2002-06-30 | Emisphere Tech Inc | Disodium salts, monohydrates, and ethanol solvates for delivering active agents |
US6458383B2 (en) * | 1999-08-17 | 2002-10-01 | Lipocine, Inc. | Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin |
CZ20021554A3 (en) | 1999-11-05 | 2002-10-16 | Emisphere Technologies, Inc. | Derivatives of a phenoxycarboxylic compound and preparations for delivering active component |
MXPA02004741A (en) | 1999-11-12 | 2003-12-11 | Emisphere Tech Inc | Liquid heparin formulation. |
US6693208B2 (en) | 1999-12-16 | 2004-02-17 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
EP1246792B1 (en) | 2000-01-13 | 2014-08-13 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
US6384278B1 (en) | 2000-02-04 | 2002-05-07 | Emisphere Technologies, Inc. | Boron-mediated amidation of carboxylic acids |
SE0000774D0 (en) | 2000-03-08 | 2000-03-08 | Astrazeneca Ab | New formulation |
WO2001070219A1 (en) | 2000-03-21 | 2001-09-27 | Emisphere Technologies, Inc. | Method of preparing alkylated salicylamides via a dicarboxylate intermediate |
AU2001275231A1 (en) | 2000-06-02 | 2001-12-11 | Emisphere Technologies, Inc. | Method of preparing salicylamides |
DE60133555T2 (en) | 2000-06-29 | 2008-09-18 | Emisphere Technologies, Inc. | COMPOUNDS AND MIXTURES FOR THE ADMINISTRATION OF AN ACTIVE AGENCY |
US7138546B2 (en) | 2000-08-18 | 2006-11-21 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
JP4707931B2 (en) | 2000-08-18 | 2011-06-22 | エミスフェアー・テクノロジーズ・インク | Active agent delivery compounds and compositions |
JP5089845B2 (en) | 2000-09-06 | 2012-12-05 | エミスフェアー・テクノロジーズ・インク | Cyanophenoxycarboxylic acid compounds and compositions for delivering active agents |
AU2001296865A1 (en) | 2000-09-06 | 2002-03-22 | Emisphere Technologies, Inc. | (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents |
MXPA03007857A (en) | 2001-03-01 | 2004-05-24 | Emisphere Tech Inc | Compounds and compositions for delivering active agents. |
US20030225300A1 (en) | 2001-04-19 | 2003-12-04 | Emisphere Technologies Inc. | Compounds and compositions for delivering active agents |
BRPI0411165A (en) | 2003-05-14 | 2006-07-11 | Emisphere Tech Inc | pharmaceutical composition, dosage unit form and methods for preparing its use |
-
2005
- 2005-05-06 MX MXPA06012841A patent/MXPA06012841A/en not_active Application Discontinuation
- 2005-05-06 EP EP05744023A patent/EP1750729A2/en not_active Withdrawn
- 2005-05-06 BR BRPI0510226-0A patent/BRPI0510226A/en not_active IP Right Cessation
- 2005-05-06 KR KR1020067025727A patent/KR20070008720A/en not_active Application Discontinuation
- 2005-05-06 WO PCT/US2005/016012 patent/WO2005107773A2/en active Application Filing
- 2005-05-06 CA CA002564866A patent/CA2564866A1/en not_active Abandoned
- 2005-05-06 AU AU2005240206A patent/AU2005240206B2/en not_active Ceased
- 2005-05-06 NZ NZ550894A patent/NZ550894A/en not_active IP Right Cessation
- 2005-05-06 JP JP2007511670A patent/JP2007536268A/en active Pending
- 2005-05-06 US US11/568,749 patent/US8039018B2/en not_active Expired - Fee Related
- 2005-05-06 RU RU2006138703/15A patent/RU2006138703A/en unknown
-
2006
- 2006-10-24 IL IL178846A patent/IL178846A0/en unknown
- 2006-12-04 MA MA29506A patent/MA28774B1/en unknown
- 2006-12-07 EC EC2006007050A patent/ECSP067050A/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP1750729A2 (en) | 2007-02-14 |
RU2006138703A (en) | 2008-06-20 |
NZ550894A (en) | 2011-02-25 |
US20070224262A1 (en) | 2007-09-27 |
AU2005240206A1 (en) | 2005-11-17 |
US8039018B2 (en) | 2011-10-18 |
AU2005240206B2 (en) | 2011-04-07 |
KR20070008720A (en) | 2007-01-17 |
BRPI0510226A (en) | 2007-10-23 |
MXPA06012841A (en) | 2007-02-15 |
WO2005107773A3 (en) | 2006-01-05 |
WO2005107773A2 (en) | 2005-11-17 |
WO2005107773A8 (en) | 2006-12-21 |
JP2007536268A (en) | 2007-12-13 |
CA2564866A1 (en) | 2005-11-17 |
ECSP067050A (en) | 2007-02-28 |
IL178846A0 (en) | 2007-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA28774B1 (en) | SOLID DOSING FORM OF WET HEPARIN | |
Yin et al. | Polymer integrity related absorption mechanism of superporous hydrogel containing interpenetrating polymer networks for oral delivery of insulin | |
US10272155B2 (en) | Use of polymeric materials with other substances for improved performance | |
US20100130426A1 (en) | Compositions containing satiogens and methods of use | |
CA2561649C (en) | Compressed pharmaceutical compositions comprising peg and electrolytes | |
MA28754B1 (en) | PREPARATION OF PHARMACEUTICAL COMPOSITIONS OF INSOLUBLE DRUGS WITH RAPID DIFFUSION WATER AND PHARMACEUTICAL COMPOSITIONS THUS PREPARED | |
Sharma et al. | Biodegradable in situ gelling system for subcutaneous administration of ellagic acid and ellagic acid loaded nanoparticles: evaluation of their antioxidant potential against cyclosporine induced nephrotoxicity in rats | |
WO2007044906A3 (en) | Compositions and methods for enhanced gastrointestinal stability of oligopeptides and polypeptides | |
EP1992336A3 (en) | Dosage form for the administration of active agents in the colon | |
WO2004080401A3 (en) | Oral insulin therapies and protocol | |
EP2609950A3 (en) | Medical device for administering a solution | |
Bernkop-Schnürch et al. | Thiomers: The next generation of mucoadhesive polymers | |
Gomez-Rubio et al. | Intestinal endometriosis as a cause of chronic abdominal pain leading to intestinal obstruction. | |
Feriani et al. | Peritoneal dialysis solutions and systems | |
KR970064597A (en) | Composition for rectal administration of drugs with gastrointestinal disorders or gastric acid degradation | |
WO2020008442A3 (en) | Biopharmaceutical agents for use in reducing lipid content in cells | |
CA2551043A1 (en) | The use of cystine or cysteine for the prevention and treatment of oxidative stress caused by haemodialysis and of acute or chronic kidney diseases | |
Kim et al. | Leukocytoclastic Vasculitis Associated with Ulcerative Colitis | |
WO2003037296A3 (en) | Methods and dosage forms for improving the bioavailability of therapeutic agents | |
Harijanti et al. | Candidosis on oral lichen planus | |
Akimoto | Acute interstitial nephritis: case report | |
JOHKO et al. | CHRONIC IDIOPATHIC COLONIC PSEUDO-OBSTRUCTION IMPROVED BY LAPAROSCOPY-ASSISTED SIGMOIDECTOMY | |
Dhia et al. | Insuffisance rénale aiguė aux antibiotiques | |
Morelle | Diclofenac/tenofovir disoproxil fumarate interaction | |
Denis-Thely et al. | P161-Miliaire sudorale pas toujours anodine! |